US does not approve AstraZeneca for chronic nasal disease

AstraZeneca said the US regulator has refused to approve the asthma drug Fasenra for the treatment of chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and congestion.
POPULAR POSTS

Rescuers pull out first survivor after landslide in Zambia
December 7, 2023

Climate Change-2023 will be the warmest year on record
December 7, 2023

The Philippines has received $5.3 billion in funding from Canada
December 7, 2023

SAG-AFTRA members vote to ratify contract that ends strike
December 7, 2023
LIVE STREAM